
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$0.3378
−US$0.0922 · -21.44%
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
前收盤價
US$0.3378
−US$0.0922 · -21.44%
盤中時間採用ET。市場資料可能有所延遲。
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
日內區間
目前US$0.3378
52週區間
目前US$0.3378
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
54
合理估值
情緒
58
多空交錯
風險
71
高風險
動能
17
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
日內區間
目前US$0.3378
52週區間
目前US$0.3378
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3630.59萬 USD | 3487.43萬 USD | 2409.28萬 USD | 434.56萬 USD | 22.84萬 USD |
| 銷貨成本 | 2438.23萬 USD | 2420.45萬 USD | 1575.36萬 USD | 264.9萬 USD | 11.78萬 USD |
| 毛利 | 1192.36萬 USD | 1066.98萬 USD | 833.92萬 USD | 169.66萬 USD | 11.06萬 USD |
| 研究與開發 | 60.43萬 USD | 93.39萬 USD | 185.58萬 USD | 81.19萬 USD | 67.22萬 USD |
| 銷售、一般及管理費用 | 1962.66萬 USD | 1493.75萬 USD | 1082.98萬 USD | 947.84萬 USD | 186.58萬 USD |
| 營業費用 | 1640.24萬 USD | 1648.19萬 USD | 1312.45萬 USD | 1037.06萬 USD | 255.07萬 USD |
| 利息收入 | 28.09萬 USD | 49.6萬 USD | 81.2萬 USD | 51.87萬 USD | — |
| 利息支出 | — | 8774 USD | 13.73萬 USD | 3.94萬 USD | 32.88萬 USD |
| 折舊和攤銷 | 33.21萬 USD | 22.35萬 USD | 14.91萬 USD | 2.52萬 USD | 1.27萬 USD |
| 營業利益 | −447.88萬 USD | −581.21萬 USD | −478.53萬 USD | −867.4萬 USD | −244.01萬 USD |
| 淨利 | −597.54萬 USD | −513.41萬 USD | −450.6萬 USD | −2674.44萬 USD | −1243.64萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。